Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors

Frontiers in Immunology(2023)10.3389/fimmu.2023.1176994Source: DataRank Database

Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors is a research paper published in Frontiers in Immunology (2023). On theSindex it has a DataRank of 0. It has been cited 24 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access24 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.73)OA: goldTopics (87)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Lu Sun ORCID,Melissa T. Bu ORCID,Yanjun Zhang ORCID,Lauren N Scott ORCID,Robert M. Prins ORCID

Live enrichment

PubMed:37435085 OpenAlex:https://openalex.org/W4382133675

National Institutes of Health

Grant: 5K08DK129829-03

Mechanisms of Thyroid Autoimmunity in Checkpoint Immunotherapy

National Institutes of Health

Grant: 5R01CA236910-03

Metastatic Clonal Heterogeneity and its Impact on Melanoma Therapeutic Resistance

FWCI

2.73

Citation Percentile

0.9%

Influential Citations

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.3389/fimmu.2023.1176994

GOLDhttps://doi.org/10.3389/fimmu.2023.1176994

publisherhttps://doi.org/10.3389/fimmu.2023.1176994

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1176994/full

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37435085

Fields of Study

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesMelanoma and MAPK PathwaysMedicineBiology0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

Immune Checkpoint InhibitorsHumansLeukocytes, MononuclearMelanomaReceptors, Antigen, B-CellAntigen PresentationCD8-Positive T-LymphocytesReceptors, CXCR5Tumor Microenvironment

Keywords

CXCL13Immune systemCancer researchTumor microenvironmentImmunologyCD8CXCR5Cytotoxic T cellBiologyAntigenAntigen presentationT cellChemokineIn vitroChemokine receptorCXCR5 (mesh)CD8-Positive T-Lymphocytes3105 Genetics (for-2020)Clinical Research (rcdc)ReceptorsLeukocytes2.1 Biological and endogenous factors32 Biomedical and Clinical Sciences (for-2020)3101 Biochemistry and cell biology (for-2020)tertiary lymphoid structure (TLS)Immune Checkpoint InhibitorsMelanomaCancerCancer (rcdc)Humans (mesh)B cell3 Good Health and Well Being (sdg)Immune Checkpoint Inhibitors (mesh)5.1 PharmaceuticalsMedical MicrobiologyImmunotherapyReceptors, CXCR5CD8-Positive T-Lymphocytes (mesh)Oncology and CarcinogenesisMononuclear6101107 Immunology (for)Receptors, Antigen, B-CellClinical Research5.1 Pharmaceuticals (hrcs-rac)interferon gamma pathwayGeneticsHumanstertiary lymphoid structure3204 Immunology (for-2020)Biomedical and Clinical SciencesAntigen Presentation (mesh)Inflammatory and immune systemB-Cell1108 Medical Microbiology (for)Immunotherapy (rcdc)2.1 Biological and endogenous factors (hrcs-rac)Cancer (hrcs-hc)RC581-607Mononuclear (mesh)Tumor Microenvironment (mesh)Inflammatory and immune system (hrcs-hc)Good Health and Well Being3211 Oncology and Carcinogenesis (for-2020)Biochemistry and cell biologyB-Cell (mesh)Leukocytes, MononuclearMelanoma (mesh)Immunologic diseases. Allergycheckpoint inhibitors